Onconova Therapeutics Inc (ONTX) 2.27 $ONTX
Onconova Therapeutics (ONTX) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 7:34AM CST
Onconova Therapeutics (ONTX) Enters Oversold Territory
ONTX: 2.27 (-0.02)
Nasdaq stocks posting largest volume increases
AP - Tue Feb 03, 5:44PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
HIHO: 3.30 (-0.17), GTWN: 17.55 (-0.40), ONTX: 2.27 (-0.02), JAXB: 10.50 (unch), KTWO: 19.75 (+0.01), MTSL: 1.52 (+0.02), HTWO: 10.20 (-0.30), OBAS: 6.25 (-0.05), GPIC: 8.47 (+0.10), SSYS: 67.16 (-0.34), WAYN: 13.85 (+0.22), ADVS: 44.18 (+0.20)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 11:47AM CST
SD: 2.09 (+0.14), RAVE: 13.57 (+0.28), SPPR: 1.63 (-0.17), PSTI: 2.91 (+0.01), ONTX: 2.27 (-0.02), LMNX: 15.45 (+0.02), NBG: 1.61 (+0.18), ARDX: 17.14 (+0.71), CSIQ: 28.84 (-0.30), LFVN: 1.11 (-0.02), XNPT: 6.69 (-0.21), GBR: 1.48 (-0.10), GENE: 8.04 (+1.90), RCII: 30.49 (+0.92), PWE: 2.45 (+0.02), PSTR: 4.63 (+0.14), SSYS: 67.16 (-0.34), ODP: 9.59 (-0.02), ENRJ: 2.81 (+0.06)
Onconova plummets as Baxter bails on development of rigosertib
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 9:51AM CST
ONTX: 2.27 (-0.02)
Onconova Announces Clinical Development Plan for Rigosertib in Higher Risk Myelodysplastic Syndrome (HR-MDS) Patients After Failure of Treatment With Hypomethylating Agents (HMAs)
GlobeNewswire - Mon Feb 02, 3:01PM CST
-- Clarity of the design of Phase 3 global replication trial of IV rigosertib in HR-MDS
ONTX: 2.27 (-0.02)
Onconova Therapeutics, Inc. to Present at Upcoming Investor Conferences in February
GlobeNewswire - Fri Jan 30, 9:40AM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced its participation in two investor conferences in February:
ONTX: 2.27 (-0.02)
Onconova Therapeutics Appoints Dr. Steven M. Fruchtman as Chief Medical Officer
GlobeNewswire - Mon Jan 12, 4:02PM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the appointment of Steven M. Fruchtman, M.D., as Chief Medical Officer and Senior Vice President, Research and Development. Dr. Fruchtman is a board certified hematologist with extensive industry experience in clinical research for myelodysplastic syndromes (MDS), hematologic malignancies and solid tumors. He will report to Thomas J. McKearn, M.D., Ph.D., the Company's President, Research and Development, and will provide worldwide strategic planning and leadership for the clinical development and registration of rigosertib and other pipeline product candidates.
ONTX: 2.27 (-0.02)
Onconova Therapeutics (ONTX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 8:30AM CST
Onconova Therapeutics (ONTX) Shares March Higher, Can It Continue?
ONTX: 2.27 (-0.02)
Onconova Therapeutics (ONTX) Looks Good: Stock Surges 18.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 8:11AM CST
Onconova Therapeutics, Inc. (ONTX) was a big mover last session, as the company saw its shares rise by over 18% on the day.
APRI: 1.84 (-0.08), ONTX: 2.27 (-0.02)
Onconova (ONTX) is Oversold: Can It Recover? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 7:54AM CST
Onconova (ONTX) is Oversold: Can It Recover?
ONTX: 2.27 (-0.02)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 4:35PM CST
AG: 6.08 (+0.17), CAMP: 18.55 (+0.07), AU: 12.33 (+0.36), UWTI: 3.71 (+0.23), ONTX: 2.27 (-0.02), NQ: 3.95 (-0.03), TPLM: 5.68 (+0.06), EPE: 12.90 (+0.56), GSAT: 2.40 (+0.08), FOLD: 8.36 (-0.11)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjf6vv/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Infinity Pharmaceuticals, Inc. - Piramal Enterprises Limited - Novartis AG - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Celgene Corporation - Immunomedics, Inc. - TG Therapeutics, Inc. - Pharmacyclics, Inc. - MorphoSys AG - Threshold Pharmaceuticals, Inc. - Onconova Therapeutics, Inc. - LFB S.A. - Advancell - Rhizen Pharmaceuticals SA - AbbVie Inc. - SpectraMab GmbH For more information visit http://www.researchandmarkets.com/research/pjf6vv/refractory
IMMU: 3.84 (unch), PCYC: 163.28 (+0.23), TGTX: 13.13 (-0.19), ONTX: 2.27 (-0.02), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AZN: 69.96 (+0.20), ABBV: 58.05 (+1.00), INFI: 15.13 (+0.55), CELGZ: 3.17 (-0.04), NVS: 102.20 (-0.17)
Myelofibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/74hp4n/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma - AstraZeneca - Bristol-Myers Squibb - Celgene - CTI BioPharma - Geron Corporation - Gilead Sciences - Incyte - Italfarmaco - KaloBios Pharmaceuticals - MEI Pharma - Nippon Shinyaku - Novartis - Onconova Therapeutics - Pfizer - PharmaEssentia - Promedior - Stemline Therapeutics - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/74...lofibrosis
KBIO: 0.45 (+0.06), GILD: 101.90 (+1.10), GERN: 3.03 (unch), ONTX: 2.27 (-0.02), CTIC: 2.23 (-0.02), BMY: 60.04 (+0.56), STML: 14.07 (-0.10), NVS: 102.20 (-0.17), MEIP: 5.00 (-0.04), CELGZ: 3.17 (-0.04), XLRN: 38.02 (+0.07)
Hairy Cell Leukemia - Pipeline Review, H2 2014
M2 - Tue Dec 09, 4:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/mrscnl/hairy_cell) has announced the addition of the "Hairy Cell Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hairy Cell Leukemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from this proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by this team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hairy Cell Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Plexxikon Inc. - Astellas Pharma Inc. - Incyte Corporation - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Inbiopro Solutions Pvt. Ltd. - Biogenomics Limited For more information visit http://www.researchandmarkets.com/research/mrscnl/hairy_cell
INCY: 75.94 (+0.28), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30), ONTX: 2.27 (-0.02), GSK: 47.94 (+1.99), STML: 14.07 (-0.10)
Onconova Announces ONTIME Data Presentations at the 2014 ASH Annual Meeting
GlobeNewswire - Sun Dec 07, 6:45PM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of data from clinical trials of rigosertib in myelodysplastic syndromes (MDS) at the 56 American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 6-9, 2014.
ONTX: 2.27 (-0.02)
Onconova Announces Data Presentation From Combination of Rigosertib and Azacitidine in MDS and Non-proliferative AML at the 2014 ASH Annual Meeting
GlobeNewswire - Sun Dec 07, 11:01AM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of data from clinical trials of rigosertib in myelodysplastic syndromes (MDS) and non-proliferative acute myeloid leukemia (AML) at the 56 American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 6-9, 2014.
ONTX: 2.27 (-0.02)
Onconova to host investor event
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 8:22AM CST
ONTX: 2.27 (-0.02)
Onconova Therapeutics to Host Analyst Event in New York City on December 12, 2014
GlobeNewswire - Fri Dec 05, 8:00AM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, will be hosting an investor and analyst event on Friday December 12, 2014 from 8:30 am to 12:00 pm ET in New York, NY. The program will focus on recent progress and advances with rigosertib for the treatment of patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML). The event will feature presentations by leading experts in the fields of oncology and hematology and Onconova management.
ONTX: 2.27 (-0.02)
Onconova Therapeutics (ONTX) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 7:34AM CST
Onconova Therapeutics (ONTX) Enters Oversold Territory
ONTX: 2.27 (-0.02)
Nasdaq stocks posting largest volume increases
AP - Tue Feb 03, 5:44PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
HIHO: 3.30 (-0.17), GTWN: 17.55 (-0.40), ONTX: 2.27 (-0.02), JAXB: 10.50 (unch), KTWO: 19.75 (+0.01), MTSL: 1.52 (+0.02), HTWO: 10.20 (-0.30), OBAS: 6.25 (-0.05), GPIC: 8.47 (+0.10), SSYS: 67.16 (-0.34), WAYN: 13.85 (+0.22), ADVS: 44.18 (+0.20)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 11:47AM CST
SD: 2.09 (+0.14), RAVE: 13.57 (+0.28), SPPR: 1.63 (-0.17), PSTI: 2.91 (+0.01), ONTX: 2.27 (-0.02), LMNX: 15.45 (+0.02), NBG: 1.61 (+0.18), ARDX: 17.14 (+0.71), CSIQ: 28.84 (-0.30), LFVN: 1.11 (-0.02), XNPT: 6.69 (-0.21), GBR: 1.48 (-0.10), GENE: 8.04 (+1.90), RCII: 30.49 (+0.92), PWE: 2.45 (+0.02), PSTR: 4.63 (+0.14), SSYS: 67.16 (-0.34), ODP: 9.59 (-0.02), ENRJ: 2.81 (+0.06)
Onconova plummets as Baxter bails on development of rigosertib
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 9:51AM CST
ONTX: 2.27 (-0.02)
Onconova Announces Clinical Development Plan for Rigosertib in Higher Risk Myelodysplastic Syndrome (HR-MDS) Patients After Failure of Treatment With Hypomethylating Agents (HMAs)
GlobeNewswire - Mon Feb 02, 3:01PM CST
-- Clarity of the design of Phase 3 global replication trial of IV rigosertib in HR-MDS
ONTX: 2.27 (-0.02)
Onconova Therapeutics, Inc. to Present at Upcoming Investor Conferences in February
GlobeNewswire - Fri Jan 30, 9:40AM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced its participation in two investor conferences in February:
ONTX: 2.27 (-0.02)
Onconova Therapeutics Appoints Dr. Steven M. Fruchtman as Chief Medical Officer
GlobeNewswire - Mon Jan 12, 4:02PM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the appointment of Steven M. Fruchtman, M.D., as Chief Medical Officer and Senior Vice President, Research and Development. Dr. Fruchtman is a board certified hematologist with extensive industry experience in clinical research for myelodysplastic syndromes (MDS), hematologic malignancies and solid tumors. He will report to Thomas J. McKearn, M.D., Ph.D., the Company's President, Research and Development, and will provide worldwide strategic planning and leadership for the clinical development and registration of rigosertib and other pipeline product candidates.
ONTX: 2.27 (-0.02)
Onconova Therapeutics (ONTX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 08, 8:30AM CST
Onconova Therapeutics (ONTX) Shares March Higher, Can It Continue?
ONTX: 2.27 (-0.02)
Onconova Therapeutics (ONTX) Looks Good: Stock Surges 18.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 05, 8:11AM CST
Onconova Therapeutics, Inc. (ONTX) was a big mover last session, as the company saw its shares rise by over 18% on the day.
APRI: 1.84 (-0.08), ONTX: 2.27 (-0.02)
Onconova (ONTX) is Oversold: Can It Recover? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 7:54AM CST
Onconova (ONTX) is Oversold: Can It Recover?
ONTX: 2.27 (-0.02)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 4:35PM CST
AG: 6.08 (+0.17), CAMP: 18.55 (+0.07), AU: 12.33 (+0.36), UWTI: 3.71 (+0.23), ONTX: 2.27 (-0.02), NQ: 3.95 (-0.03), TPLM: 5.68 (+0.06), EPE: 12.90 (+0.56), GSAT: 2.40 (+0.08), FOLD: 8.36 (-0.11)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjf6vv/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Infinity Pharmaceuticals, Inc. - Piramal Enterprises Limited - Novartis AG - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Celgene Corporation - Immunomedics, Inc. - TG Therapeutics, Inc. - Pharmacyclics, Inc. - MorphoSys AG - Threshold Pharmaceuticals, Inc. - Onconova Therapeutics, Inc. - LFB S.A. - Advancell - Rhizen Pharmaceuticals SA - AbbVie Inc. - SpectraMab GmbH For more information visit http://www.researchandmarkets.com/research/pjf6vv/refractory
IMMU: 3.84 (unch), PCYC: 163.28 (+0.23), TGTX: 13.13 (-0.19), ONTX: 2.27 (-0.02), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AZN: 69.96 (+0.20), ABBV: 58.05 (+1.00), INFI: 15.13 (+0.55), CELGZ: 3.17 (-0.04), NVS: 102.20 (-0.17)
Myelofibrosis - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/74hp4n/myelofibrosis) has announced the addition of the "Myelofibrosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myelofibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelofibrosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myelofibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myelofibrosis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acceleron Pharma - AstraZeneca - Bristol-Myers Squibb - Celgene - CTI BioPharma - Geron Corporation - Gilead Sciences - Incyte - Italfarmaco - KaloBios Pharmaceuticals - MEI Pharma - Nippon Shinyaku - Novartis - Onconova Therapeutics - Pfizer - PharmaEssentia - Promedior - Stemline Therapeutics - Threshold Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/74...lofibrosis
KBIO: 0.45 (+0.06), GILD: 101.90 (+1.10), GERN: 3.03 (unch), ONTX: 2.27 (-0.02), CTIC: 2.23 (-0.02), BMY: 60.04 (+0.56), STML: 14.07 (-0.10), NVS: 102.20 (-0.17), MEIP: 5.00 (-0.04), CELGZ: 3.17 (-0.04), XLRN: 38.02 (+0.07)
Hairy Cell Leukemia - Pipeline Review, H2 2014
M2 - Tue Dec 09, 4:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/mrscnl/hairy_cell) has announced the addition of the "Hairy Cell Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hairy Cell Leukemia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from this proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by this team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hairy Cell Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Plexxikon Inc. - Astellas Pharma Inc. - Incyte Corporation - Stemline Therapeutics, Inc. - Onconova Therapeutics, Inc. - Inbiopro Solutions Pvt. Ltd. - Biogenomics Limited For more information visit http://www.researchandmarkets.com/research/mrscnl/hairy_cell
INCY: 75.94 (+0.28), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30), ONTX: 2.27 (-0.02), GSK: 47.94 (+1.99), STML: 14.07 (-0.10)
Onconova Announces ONTIME Data Presentations at the 2014 ASH Annual Meeting
GlobeNewswire - Sun Dec 07, 6:45PM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of data from clinical trials of rigosertib in myelodysplastic syndromes (MDS) at the 56 American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 6-9, 2014.
ONTX: 2.27 (-0.02)
Onconova Announces Data Presentation From Combination of Rigosertib and Azacitidine in MDS and Non-proliferative AML at the 2014 ASH Annual Meeting
GlobeNewswire - Sun Dec 07, 11:01AM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of data from clinical trials of rigosertib in myelodysplastic syndromes (MDS) and non-proliferative acute myeloid leukemia (AML) at the 56 American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 6-9, 2014.
ONTX: 2.27 (-0.02)
Onconova to host investor event
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 8:22AM CST
ONTX: 2.27 (-0.02)
Onconova Therapeutics to Host Analyst Event in New York City on December 12, 2014
GlobeNewswire - Fri Dec 05, 8:00AM CST
Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, will be hosting an investor and analyst event on Friday December 12, 2014 from 8:30 am to 12:00 pm ET in New York, NY. The program will focus on recent progress and advances with rigosertib for the treatment of patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML). The event will feature presentations by leading experts in the fields of oncology and hematology and Onconova management.
ONTX: 2.27 (-0.02)
